Cipla is one of India's most recognized pharmaceutical companies, with more than eight decades of experience in developing, manufacturing, and supplying high-quality medicines. The company has built a strong presence across India and international markets, with operations spanning branded medicines, generic pharmaceuticals, trade generics, and consumer healthcare. Its broad portfolio covers multiple therapeutic areas, making Cipla a prominent name for businesses and healthcare professionals looking for established pharmaceutical products.

Cipla's India business has a strong presence across key therapeutic segments including respiratory, anti-infectives, cardiac, anti-diabetic, gastro-intestinal, urology, and dermatology. Its portfolio includes medicines in multiple dosage forms and therapeutic categories, supporting diverse healthcare requirements. The company's recent reporting also highlights strong performance across respiratory, cardiac, anti-diabetic, anti-infective and derma therapies.

The company is committed to making healthcare more accessible by focusing on quality, affordability, availability, and patient-centric innovation. Cipla's global footprint extends across more than 100 countries, supported by modern manufacturing capabilities and a large portfolio of pharmaceutical products.

With its extensive product portfolio, established reputation, strong distribution network, and commitment to quality healthcare, Cipla remains a prominent pharmaceutical company for general and multi-therapeutic medicine requirements.